Effect of Home-Based Transcranial Direct Current Stimulation on Pain in Patients With Rheumatoid Arthritis With Low Inflammatory Activity
tDCS RA
1 other identifier
interventional
34
1 country
1
Brief Summary
Rheumatoid arthritis (RA) is a highly complex inflammatory autoimmune disease. Several drugs have been developed in recent decades to target the immune components of inflammation. However, even with effective anti-inflammatory and immunosuppressive therapies for controlling RA, many patients still report significant levels of chronic pain due to CNS neuroplasticity, perpetuating physical disability, psychosocial problems, decreased work activity, and poor quality of life. In addition, chronic pain can lead to increased public spending due to the need for more medical visits, ineffective drug treatments, and financial disability benefits. Transcranial stimulation (a noninvasive neural stimulation technique with minimal adverse effects and easy home use) has been a promising adjunct tool in the treatment of chronic pain and psychological disorders in diseases that affect the central nervous system in the long term. Thus, exploring transcranial direct current stimulation in RA patients with low levels of inflammation could impact on improving pain, functionality, psychological aspects and overall quality of life, as well as reducing healthcare costs for society.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2024
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
April 7, 2025
CompletedFirst Posted
Study publicly available on registry
September 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 22, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 22, 2028
September 9, 2025
April 1, 2025
5 years
April 7, 2025
September 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
VAS pain
Visual Analogue Scale for pain
Visual Analog Scale (VAS, 0-100 mm; higher scores indicate worse pain) assessed at baseline (Day 1), after 10 days of tDCS treatment, at Week 4 of tDCS treatment (end of treatment), and at 3, 6, 9, and 12 months post-treatment.
Study Arms (2)
Acitve tDCS
ACTIVE COMPARATOR2 mA, 20 minutes/day, 5 days/week, for 4 weeks, applied at home under remote supervision.
Sham tDCS
SHAM COMPARATORSame parameters as active tDCS, but current was ramped down after 30 seconds to mimic sensation without delivering stimulation.
Interventions
Eligibility Criteria
You may qualify if:
- Participants aged 18-70 with RA.
- Participants with generalized pain ≥ 40 mm on the VAS-Pain scale, lasting over 3 months, and not of mechanical or inflammatory origin, as assessed by a certified rheumatologist.
- Evidence of low inflammatory markers, including with C-reactive protein (CRP) \<10 mg/dL and sedimentation rate (ESR) \<20 mm/h, and stable treatment for PsA for at least 6 months prior to study enrollment.
You may not qualify if:
- History of brain surgery, traumatic brain injury, stroke, previous intracranial metal implantation, pregnancy, or breastfeeding.
- Previous history of autoimmune diseases other than RA.
- History of neurological diseases.
- Previous history of neoplasia.
- History of any other uncompensated clinical disease.
- Use of illicit drugs within the past 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90880390, Brazil
Related Publications (1)
Caumo W, Lopes Ramos R, Vicuna Serrano P, da Silveira Alves CF, Medeiros L, Ramalho L, Tomeddi R, Bruck S, Boher L, Sanches PRS, Silva DP Jr, Ls Torres I, Fregni F. Efficacy of Home-Based Transcranial Direct Current Stimulation Over the Primary Motor Cortex and Dorsolateral Prefrontal Cortex in the Disability Due to Pain in Fibromyalgia: A Factorial Sham-Randomized Clinical Study. J Pain. 2024 Feb;25(2):376-392. doi: 10.1016/j.jpain.2023.09.001. Epub 2023 Sep 7.
PMID: 37689323BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator; PhD Student in Medical Sciences at the Federal University of Rio Grande do Sul
Study Record Dates
First Submitted
April 7, 2025
First Posted
September 9, 2025
Study Start
January 1, 2024
Primary Completion (Estimated)
December 22, 2028
Study Completion (Estimated)
December 22, 2028
Last Updated
September 9, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share
The Individual Patient Data (IPD) will not be shared due to privacy and confidentiality concerns, as well as the protection of sensitive patient information. Additionally, there may be legal or regulatory restrictions that prevent the release of such data. Sharing of IPD could also raise ethical issues regarding informed consent and the use of data beyond the initial scope of the study.